

GLAND PHARMA LIMITED

May 20, 2022

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Newspaper advertisement pertaining to Audited Financial Results of Q4 FY 2022

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 as amended, please find enclosed copies of the newspaper advertisement pertaining to Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022. The advertisements were published in English and Telugu newspapers.

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi (ABAD)
Company Secretary and Compliance Officer

Encl: As mentioned above



The Economic Times- May 20, 2022

Companies: Pursuit of Profit 18



GLAND PHARMA LIMITED

Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimalisamma 'X' Roads, D.P. Pally,
Dundigal, Dundigal-Gandimalisamma Mandal, Medchal-Malkojgiri District, Hyderabad 500 043, Telangana, India. Cih: L24239TG1978PLC002276 Tel: +91 84556 99999

Website: www.glandpharma.com; ernail: investors@glandpharma.com

EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

Particulars	Quarter ended			Year ended	
	31-Mar-22 Audited	31-Dec-21 Unaudited	31-Mar-21 Audited	31-Mar-22 Audited	31-Mar-21 Audited
Profit before tax	3,804.84	3,655.63	3,489,43	16,185.52	13,348.10
Profit for the period/year	2,859.02	2,730.29	2,604.09	12,116.64	9,969.63
Total comprehensive income (after taxes)	2,856.29	2,739.22	2,607.55	12,112.06	9,960.9
Paid up equity share capital (Face value of ₹1/- each)	164.30	164.30	163.59	164.30	163.59
Other equity			- 1	71,411.91	58,868.83
Earnings per equity share (Face value of ₹1/- each): (Not annualised for the quarter)					
Basic (₹)	17.40	16.62	15.93	73.81	63.07
Diluted (₹)	17.36	16.62	15.88	73.64	62.99

Particulars	Quarter ended			Year ended	
	31-Mar-22 Audited	31-Dec-21 Unaudited	31-Mar-21 Audited	31-Mar-22 Audited	31-Mar-21 Audited
Profit before tax	3,805.58	3,659.18	3,489.85	16,190.43	13,348.52
Profit for the period/year	2,859.76	2,733.84	2,604.51	12,121.55	9,970.05


- The Audited Consolidated Financial Results for the quarter and financial year ended March 31, 2022 ("Audited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 19, 2022.
- The public issue net proceeds of the Initial Public Offer are being utilised as per the objects stated in the Prospectus of the Company. Accordingly we don't have any deviations or variations to be reported in the utilisation of the public issue proceeds for the quarter ended March 31, 2022.
- S. The above is an extract of the detailed format of the quarter and financial year ended Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the Company's website (www.glandpharma.com) and on the website of the National Stock Exchange of India Limited (www.nseindia.com) and BSE Limited (www.bseindia.com).


For and on behalf of the Board Gland Pharma Limited Srinivas Sadu Managing Director and CEO DIN No. 06900659

Hyderabad May 19, 2022



Financial Express- May 20, 2022







Andhra Prabha- May 20, 2022

శుక్రవారం 20 మే 2022 - హైదరాబాద్ 5

